Disruptions to the circadian clock have been implicated in tumor development, progression, and responses to treatment across different types of cancers [12,13,14,15,16], which has a bearing on tailoring targeted therapeutic strategies to specific types of cancer [17,18]. This evidence concerns the gene CLOCK and neoplasm.